In this study, we reported that CUDC‐907, a dual PI3K and HDAC inhibitor, has a strong impact on the microenvironment of malignant B cells and is highly effective in killing CLL cells. Here, HDAC9 is linked to B-cell chronic lymphocytic leukemia.